
	Three Months Ended				Nine Months Ended
	October 2, 2020		September 27, 2019		October 2, 2020		September 27, 2019
	(In thousands, except share and per share data)
Computation of Net income (loss) per share from continuing operations - basic:
Net income (loss) from continuing operations attributable to Colfax Corporation (1)	$	16,047	$	2,901	$	20,319	$	(18,636)
Weighted-average shares of Common stock outstanding – basic	136,832,909		136,121,017		136,730,112		135,440,566
Net income (loss) per share from continuing operations – basic	$	0.12	$	0.02	$	0.15	$	(0.14)

Computation of Net income (loss) per share from continuing operations - diluted:
Net income (loss) from continuing operations attributable to Colfax Corporation (1)	$	16,047	$	2,901	$	20,319	$	(18,636)
Weighted-average shares of Common stock outstanding – basic	136,832,909		136,121,017		136,730,112		135,440,566
Net effect of potentially dilutive securities - stock options, restricted stock units and tangible equity units	1,257,701		929,143		2,339,794		—
Weighted-average shares of Common stock outstanding – diluted	138,090,610		137,050,160		139,069,906		135,440,566
Net income (loss) per share from continuing operations – diluted	$	0.12	$	0.02	$	0.15	$	(0.14)

(1) Net income (loss) from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income (loss) from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $0.8 million and $2.2 million for the three and nine months ended October 2, 2020, and $0.9 million and $3.1 million for the three and nine months ended September 27, 2019, respectively.

For all periods presented, the weighted-average shares of Common stock outstanding - basic includes the impact of 18.4 million shares related to the issuance of Colfax’s tangible equity units. For the nine months ended October 2, 2020, the weighted-average shares of Common stock outstanding - diluted includes the impact of an additional 1.2 million potentially issuable dilutive shares related to Colfax’s tangible equity units as a result of the Company’s share price in March 2020. See Note 8, “Equity” for details.

The weighted-average computation of the dilutive effect of potentially issuable shares of Common stock under the treasury stock method for the three and nine months ended October 2, 2020 excludes 2.8 million and 4.2 million, respectively, of outstanding stock-based compensation awards as their inclusion would be anti-dilutive.

The weighted-average computation of the dilutive effect of potentially issuable shares of Common stock under the treasury stock method for the three and nine months ended September 27, 2019 excludes 4.4 million and 4.6 million, respectively, of outstanding stock-based compensation awards as their inclusion would be anti-dilutive.